Advancing Transplantation Outcomes in Children

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Kidney Transplant
Interventions
DRUG

Sirolimus

Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily

BIOLOGICAL

Belatacept

Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24

DRUG

Mycophenolate Mofetil

Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID

DRUG

Tacrolimus (Group1)

Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant

DRUG

Anti-Thymocyte Globulin (ATG)

Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function

DRUG

Tacrolimus (Group 2)

Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels

Trial Locations (20)

10461

NOT_YET_RECRUITING

New York Medical College/Boston Children's Health Physicians, Westchester

15224

RECRUITING

UPMC Children's Hospital of Pittsburgh (Site #: 71008), Pittsburgh

19104

RECRUITING

Children's Hospital of Philadelphia (Site #: 71091), Philadelphia

19803

RECRUITING

Nemours Children's Health (Site #: 71042), Wilmington

20010

RECRUITING

Children's National Medical Center (Site #: 71039), Washington D.C.

21287

RECRUITING

Johns Hopkins Children's Center (Site #: 71025), Baltimore

27710

RECRUITING

Duke University (Site #: 71033), Durham

35233

RECRUITING

University of Alabama at Birmingham (Site # 71038), Birmingham

45229

RECRUITING

Cincinnati Children's Hospital Medical Center (Site #: 71017), Cincinnati

49503

RECRUITING

Helen DeVos Children's Hospital (Site #: 71035), Grand Rapids

60611

RECRUITING

Ann and Robert H. Lurie Children's Hospital of Chicago (Site #: 71016), Chicago

63110

RECRUITING

Washington University/St. Louis Children's Hospital (Site #: 71006), St Louis

77030

RECRUITING

Texas Children's Hospital (Baylor) (Site #: 71005), Houston

80045

RECRUITING

Children's Hospital of Colorado (Site #: 71019), Aurora

90027

NOT_YET_RECRUITING

Children's Hospital of Los Angeles (Site #: 71036), Los Angeles

90048

RECRUITING

Cedars-Sinai Medical Center (Site #: 71026), Los Angeles

90095

RECRUITING

Mattel Children's Hospital, UCLA (Site #: 71012), Los Angeles

92123

RECRUITING

UCSD Rady Children's Hospital (Site #: 71037), San Diego

98105

RECRUITING

Seattle Children's Hospital (Site #: 71041), Seattle

02215

RECRUITING

Boston Children's Hospital (Site #: 71001), Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH